140 research outputs found
Application of HOSVD to Aerodynamics. The Problem of Shock Waves
Efficient interpolation in aerodynamic databases is important for the aeronautic industry because of its implication on both the cost and time needed to complete design cycles. In this study a method based on high-order singular value decomposition is presented focusing on the problems associated with the shock wave like structures that do not suit well with this kind of methods. To illustrate the methodology, the flow around a two-dimensional airfoil is considered at a Reynolds number of 20 × 106 with three free parameters, namely, the Mach number, the angle of attack, and the flap deflection angle in the ranges of [0.4, 0.8], [¿3º, 3º], and [¿5º, 5º], respectively. The method is robust in the sense of being able to deal with very different flow topologies
Sandwich-Type Electrochemical Paper-Based Immunosensor for Claudin 7 and CD81 Dual Determination on Extracellular Vesicles from Breast Cancer Patients
This study is focused on identifying novel epithelial markers in circulating extracellular vesicles (EVs) through the development of a dual sandwich-type electrochemical paper-based immunosensor for Claudin 7 and CD81 determination, as well as its validation in breast cancer (BC) patients. This immunosensor allows for rapid, sensitive, and label-free detection of these two relevant BC biomarkers. Under optimum conditions, the limit of detection for Claudin 7 was 0.4 pg mL-1, with a wide linear range of 2 to 1000 pg mL-1, while for CD81, the limit of detection was 3 pg mL-1, with a wide linear range of 0.01 to 10 ng mL-1. Finally, we validated Claudin 7 and CD81 determination in EVs from 60 BC patients and 20 healthy volunteers, reporting higher diagnostic accuracy than the one observed with classical diagnostic markers. This analysis provides a low-cost, specific, versatile, and user-friendly strategy as a robust and reliable tool for early BC diagnosis.Fil: Ortega, Francisco G.. Balearic Islands Health Research Institute; EspañaFil: Regiart, Matías D.. Universidade de Sao Paulo; BrasilFil: Rodríguez Martínez, Alba. Universidad de Granada; EspañaFil: De Miguel-Pérez, Diego. Universidad de Granada; EspañaFil: Serrano, María J.. Universidad de Granada; EspañaFil: Lorente, José A.. Universidad de Granada; EspañaFil: Tortella, Gonzalo. Universidad de La Frontera; ChileFil: Rubilar, Olga. Universidad de La Frontera; ChileFil: Sapag, Manuel Karim. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Luis. Instituto de Física Aplicada "Dr. Jorge Andrés Zgrablich". Universidad Nacional de San Luis. Facultad de Ciencias Físico Matemáticas y Naturales. Instituto de Física Aplicada "Dr. Jorge Andrés Zgrablich"; ArgentinaFil: Bertotti, Mauro. Universidade de Sao Paulo; BrasilFil: Fernández Baldo, Martín Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Luis. Instituto de Química de San Luis. Universidad Nacional de San Luis. Facultad de Química, Bioquímica y Farmacia. Instituto de Química de San Luis; Argentin
Aerosol radiative forcing efficiency in the UV region over southeastern Mediterranean: VELETA2002 campaign
Atmospheric aerosol effects on spectral global UV irradiance were evaluated during the VELETA2002 field campaign between 8 and 19 July 2002 in southeast Spain. In the first stage, seven UV spectroradiometer and six CIMEL Sun photometer measurements were carried out simultaneously, allowing them to be calibrated and intercompared. The mean ratio obtained for the global irradiance between the spectroradiometers, with regards to a reference instrument, ranges from 0.98 up to 1.04 with standard deviations that oscillate between ±0.01 and ±0.17. In particular, the two spectroradiometers used to obtain the aerosol forcing efficiencies have a ratio of 1.000 ± 0.001. The aerosol optical depth (AOD) obtained with the CIMEL Sun photometers has a standard deviation of lower than ±0.01 for all the channels. Under clear sky conditions, the diurnal aerosol forcing efficiency (DDFe) and fractional diurnal forcing efficiency (DFDFe) was calculated for two Mediterranean stations: Armilla (691 m.a.s.l.) within the boundary layer and Sabinas (2200 m.a.s.l) on the lower limit of the free troposphere and 25 km away from the first station. The DDFe values obtained at Armilla range between _2.72 ± 0.45 W m_2/t380 and _2.88 ± 0.45 W m_2/t440 and between _3.22 ± 0.61 W m_2/t380 and _3.40 ± 0.62 W m_2/t440 at Sabinas station; the DFDFe values range from _8.0 ± 1.4%/t380 to _8.6 ± 1.3%/t440 and _12.0 ± 2.3%/t380 to _12.6 ± 2.3%/t440 at the two stations, respectively. Also, an experimental aerosol transmittance factor, CT, used to obtain UV satellite derived products was found as a result of the dependence of the global irradiance with the AOD, under cloudless conditions. The average aerosol attenuation factor, h, obtained from the CT, is 6 ± 2% under weakly absorbing aerosols, with a negligible spectral dependence.This work was supported by CICYT–MCYT through the coordinated projects CGL2004-05984-C07-05 and CGL2005-03428-C04-02
Hepatocellular carcinoma risk-stratification based on ASGR1 in circulating epithelial cells for cancer interception
Purpose: Lack of diagnostic and prognostic biomarkers in hepatocellular
carcinoma impedes stratifying patients based on their risk of developing
cancer. The aim of this study was to evaluate phenotypic and genetic
heterogeneity of circulating epithelial cells (CECs) based on
asialoglycoprotein receptor 1 (ASGR1) and miR-122-5p expression as
potential diagnostic and prognostic tools in patients with hepatocellular
carcinoma (HCC) and liver cirrhosis (LC).
Methods: Peripheral blood samples were extracted from LC and HCC patients
at different disease stages. CECs were isolated using positive immunomagnetic
selection. Genetic and phenotypic characterization was validated by double
immunocytochemistry for cytokeratin (CK) and ASGR1 or by in situ hybridization
with miR-122-5p and CECs were visualized by confocal microscopy.
Results: The presence of CECs increased HCC risk by 2.58-fold, however, this
was only significant for patients with previous LC (p = 0.028) and not for those
without prior LC (p = 0.23). Furthermore, the number of CECs lacking
ASGR1 expression correlated significantly with HCC incidence and absence
of miR-122-5p expression (p = 0.014; r = 0.23). Finally, overall survival was
significantly greater for patients at earlier cancer stages (p = 0.018), but this difference was only maintained in the group with the presence of CECs (p =
0.021) whereas progression-free survival was influenced by the absence of
ASGR1 expression.
Conclusion: Identification and characterization of CECs by ASGR1 and/or miR-
122-5p expression may be used as a risk-stratification tool in LC patients, as it
was shown to be an independent prognostic and risk-stratification marker in LC
and early disease stage HCC patients
Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis
Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis
INTRODUCTION: Matrix metalloproteinases (MMPs) play a role in infectious diseases through extracellular matrix (ECM) degradation, which favors the migration of immune cells from the bloodstream to sites of inflammation. Although higher levels of MMP-9 and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) have been found in small series of patients with sepsis, MMP-10 levels have not been studied in this setting. The objective of this study was to determine the predictive value of MMP-9, MMP-10, and TIMP-1 on clinical severity and mortality in a large series of patients with severe sepsis.
METHODS: This was a multicenter, observational, and prospective study carried out in six Spanish Intensive Care Units. We included 192 (125 surviving and 67 nonsurviving) patients with severe sepsis and 50 age- and sex-matched healthy controls in the study. Serum levels of MMP-9, MMP-10, TIMP-1, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-10 were measured in patients with severe sepsis at the time of diagnosis and in healthy controls.
RESULTS: Sepsis patients had higher levels of MMP-10 and TIMP-1, higher MMP-10/TIMP-1 ratios, and lower MMP-9/TIMP-1 ratios than did healthy controls (P < 0.001). An association was found between MMP-9, MMP-10, TIMP-1, and MMP-9/TIMP-1 ratios and parameters of sepsis severity, assessed by the SOFA score, the APACHE-II score, lactic acid, platelet count, and markers of coagulopathy. Nonsurviving sepsis patients had lower levels of MMP-9 (P = 0.037), higher levels of TIMP-1 (P < 0.001), lower MMP-9/TIMP-1 ratio (P = 0.003), higher levels of IL-10 (P < 0.001), and lower TNF-alpha/IL-10 ratio than did surviving patients. An association was found between MMP-9, MMP-10, and TIMP-1 levels, and TNF-alpha and IL-10 levels. The risk of death in sepsis patients with TIMP-1 values greater than 531 ng/ml was 80% higher than that in patients with lower values (RR = 1.80; 95% CI = 1.13 to 2.87;P = 0.01; sensitivity = 0.73; specificity = 0.45).
CONCLUSIONS: The novel findings of our study on patients with severe sepsis (to our knowledge, the largest series reporting data about MMP levels in sepsis) are that reduced MMP-9/TIMP-1 ratios and increased MMP-10 levels may be of great pathophysiologic significance in terms of severity and mortality, and that TIMP-1 levels may represent a biomarker to predict the clinical outcome of patients with sepsis
Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease
BACKGROUND AND AIMS: To evaluate the clinical outcomes in patients with IBD after switching from Remicade® to CT-P13 in comparison with patients who maintain Remicade®. METHODS: Patients under Remicade® who were in clinical remission with standard dosage at study entry were included. The ''switch cohort'' [SC] comprised patients who made the switch from Remicade® to CT-P13, and the ''non-switch'' cohort [NC] patients remained under Remicade®. RESULTS: A total of 476 patients were included: 199 [42%] in the SC and 277 [58%] in the NC. The median follow-up was 18 months in the SC and 23 months in the NC [p < 0.01]. Twenty-four out of 277 patients relapsed in the NC; the incidence of relapse was 5% per patient-year. The cumulative incidence of relapse was 2% at 6 months and 10% at 24 months in this group. Thirty-eight out of 199 patients relapsed in the SC; the incidence rate of relapse was 14% per patient-year. The cumulative incidence of relapse was 5% at 6 months and 28% at 24 months. In the multivariate analysis, the switch to CT-P13 was associated with a higher risk of relapse (HR = 3.5, 95% confidence interval [CI] = 2-6). Thirteen percent of patients had adverse events in the NC, compared with 6% in the SC [p < 0.05]. CONCLUSIONS: Switching from Remicade® to CT-P13 might be associated with a higher risk of clinical relapse, although this fact was not supported in our study by an increase in objective markers of inflammation. The nocebo effect might have influenced this result. Switching from Remicade® to CT-P13 was safe
SARS-CoV-2 Infection Triggers Auto-Immune Response in ARDS
Acute respiratory distress syndrome (ARDS) is a severe pulmonary disease, which is one of the major complications in COVID-19 patients. Dysregulation of the immune system and imbalances in cytokine release and immune cell activation are involved in SARS-CoV-2 infection. Here, the inflammatory, antigen, and auto-immune profile of patients presenting COVID-19-associated severe ARDS has been analyzed using functional proteomics approaches. Both, innate and humoral responses have been characterized through acute-phase protein network and auto-antibody signature. Severity and sepsis by SARS-CoV-2 emerged to be correlated with auto-immune profiles of patients and define their clinical progression, which could provide novel perspectives in therapeutics development and biomarkers of COVID-19 patients. Humoral response in COVID-19 patients’ profile separates with significant differences patients with or without ARDS. Furthermore, we found that this profile can be correlated with COVID-19 severity and results more common in elderly patients.We gratefully acknowledge financial support from the Spanish Health Institute Carlos III (ISCIII) for the grants: FIS PI14/01538, FIS PI17/01930, and CB16/12/00400. This research work was also funded by the European Commission – NextGenerationEU, through CSIC's Global Health Platform (PTI Salud Global) We also acknowledge Fondos FEDER (EU) and Junta Castilla-León (COVID19 grant COV20EDU/00187). The Proteomics Unit belongs to ProteoRed, PRB3-ISCIII, supported by grant PT17/0019/0023, of the PE I + D + I 2017-2020, funded by ISCIII and FEDER. AL-V is supported by the VIII Centenario-USAL PhD Program. PJ-V is supported by the JCYL PhD Program “Nos Impulsa-JCYL” and scholarship JCYL-EDU/601/2020. EXOHEP-CM S2017/BMD3727 by Comunidad de Madrid and Fondos FEDER (to JL and RH) and PI19/01091 by ISCIII (to RH).Peer reviewe
Integrated treatment of first episode psychosis with online training (e-learning): study protocol for a randomised controlled trial
BackgroundThe integrated treatment of first episode psychosis has been shown to improve functionality and negative symptoms in previous studies. In this paper, we describe a study of integrated treatment (individual psychoeducation complementary to pharmacotherapy) versus treatment as usual, comparing results at baseline with those at 6-month re-assessment (at the end of the study) for these patients, and online training of professionals to provide this complementary treatment, with the following objectives: 1) to compare the efficacy of individual psychoeducation as add-on treatment versus treatment as usual in improving psychotic and mood symptoms; 2) to compare adherence to medication, functioning, insight, social response, quality of life, and brain-derived neurotrophic factor, between both groups; and 3) to analyse the efficacy of online training of psychotherapists.Methods/designThis is a single-blind randomised clinical trial including patients with first episode psychosis from hospitals across Spain, randomly assigned to either a control group with pharmacotherapy and regular sessions with their psychiatrist (treatment as usual) or an intervention group with integrated care including treatment as usual plus a psychoeducational intervention (14 sessions). Training for professionals involved at each participating centre was provided by the coordinating centre (University Hospital of Álava) through video conferences. Patients are evaluated with an extensive battery of tests assessing clinical and sociodemographic characteristics (Positive and Negative Syndrome Scale, State-Trait Anxiety Inventory, Liebowitz Social Anxiety Scale, Hamilton Rating Scale for Depression, Scale to Assess Unawareness of Mental Disorders, Strauss and Carpenter Prognostic Scale, Global Assessment of Functioning Scale, Morisky Green Adherence Scale, Functioning Assessment Short Test, World Health Organization Quality of Life instrument WHOQOL-BREF (an abbreviated version of the WHOQOL-100), and EuroQoL questionnaire), and brain-derived neurotrophic factor levels are measured in peripheral blood at baseline and at 6 months. The statistical analysis, including bivariate analysis, linear and logistic regression models, will be performed using SPSS.DiscussionThis is an innovative study that includes the assessment of an integrated intervention for patients with first episode psychosis provided by professionals who are trained online, potentially making it possible to offer the intervention to more patients.Trial registrationNCT01783457 clinical trials.gov. Date of registration in primary registry 23 January 2013
- …